Makes sense.
It's a bit hard to draw conclusions regarding PFS from the data they've given us but obviously they've got a bit more data than us and know it's positive. As someone else mentioned too - only 3 or 4 of the 14 were on the 400mg dose that was ultimately chosen for 2a.
Market still staying away from this one until capital sorted out. I'm still expecting a cap raise reasonably soon.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-13
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.003(4.48%) |
Mkt cap ! $19.01M | |||
| Open | High | Low | Value | Volume |
| 6.7¢ | 7.0¢ | 6.7¢ | $8.029K | 117.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 72000 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 136371 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.7¢ |
Change
0.003 ( 1.52 %) |
||||
| Open | High | Low | Volume | ||
| 6.7¢ | 6.7¢ | 6.7¢ | 15136 | ||
| Last updated 10.34am 31/05/2024 ? | |||||
| ATX (ASX) Chart |